Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability

Janet H. Ford, David W. Ayer, Qi Zhang, Jeffrey N. Carter, Elizabeth Leroux, Vladimir Skljarevski, Sheena K. Aurora, Antje Tockhorn-Heidenreich, Richard B. Lipton

Research output: Contribution to journalArticle

3 Scopus citations


OBJECTIVE: To evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated with galcanezumab or placebo. METHODS: Patients with episodic migraine (4-14 monthly migraine headache days) were treated with either galcanezumab (Evaluation of LY2951742 in the Prevention of Episodic Migraine [EVOLVE]-1: 120 mg n = 210, 240 mg n = 208; EVOLVE-2: 120 mg n = 226, 240 mg n = 220) or placebo (EVOLVE-1 n = 425; EVOLVE-2 n = 450) during 6 months of treatment. Migraine-Specific Quality of Life Questionnaire v2.1 (MSQv2.1) measured the effect of migraine on patient functioning (physical and emotional) in 3 domains, and the Migraine Disability Assessment (MIDAS) quantified headache-related disability associated with missed or reduced productivity at work or home and social events. Both were collected at baseline and during the treatment period (MSQv2.1 = monthly; MIDAS = months 3 and 6 only). RESULTS: Differences in MSQv2.1 total score least squares (LS) mean change from baseline (month 4-6) for galcanezumab (120 and 240 mg, respectively) were superior to placebo (EVOLVE-1 = 7.3 and 6.7 [both p < 0.001]; EVOLVE-2 = 8.5 and 7.3 [both p < 0.001]). Differences were similar for all domain scores (p < 0.001 for both galcanezumab doses compared with placebo), were observed as early as month 1, and were sustained for 6 months for most domains. Differences of MIDAS LS mean change from baseline (month 6) for galcanezumab (120 and 240 mg, respectively) compared with placebo were: EVOLVE-1 = -6.3 (p < 0.001) and -5.2 (p = 0.002); EVOLVE-2 = -9.2 and -8.2 (both p < 0.001). CONCLUSIONS: Patients with episodic migraine treated with galcanezumab reported significant and clinically meaningful improvements in daily functioning and decreased disability compared with patients who received placebo. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, galcanezumab (120 mg or 240 mg) given once monthly improved functioning and reduced disability.

Original languageEnglish (US)
Pages (from-to)e508-e517
Issue number5
StatePublished - Jul 30 2019

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability'. Together they form a unique fingerprint.

  • Cite this

    Ford, J. H., Ayer, D. W., Zhang, Q., Carter, J. N., Leroux, E., Skljarevski, V., Aurora, S. K., Tockhorn-Heidenreich, A., & Lipton, R. B. (2019). Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability. Neurology, 93(5), e508-e517.